Valion Bio
VBIO
6 hedge funds and large institutions have $567K invested in Valion Bio in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
204% more capital invested
Capital invested by funds: $187K → $567K (+$380K)
100% more funds holding
Funds holding: 3 → 6 (+3)
5.21% more ownership
Funds ownership: 7.25% → 12.46% (+5.2%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LM
Lasry Marc
|
+$351K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$186K |
| 3 |
Citigroup
New York
|
+$4.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$16.7K |
| 2 |
MG
Marex Group
London,
|
-$3.02K |
VBIO Hedge Fund Activity: Q3 2025 in Review
6 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q3 2025, worth a combined $567K — up 204% from $187K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VBIO positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Lasry Marc, opening a new position worth an estimated $351K. The largest seller was UBS Group, cutting an estimated $16.7K.
- 6 institutional investors held Valion Bio (VBIO) as of Q3 2025, up from 3 in Q2 2025.
- Funds reported $567K of Valion Bio stock for Q3 2025, up 204% quarter-over-quarter.
- 3 funds opened new Valion Bio positions in Q3 2025 and 0 closed out, a net change of +3 holders.
- The largest Valion Bio buyer in Q3 2025 was Lasry Marc, an estimated $351K added.
- The largest Valion Bio seller in Q3 2025 was UBS Group, an estimated $16.7K sold.
Based on aggregated 13F filings for Q3 2025.